Akasi Pharma

About

At Akasi Pharma, we are dedicated to develping safe and efficacious non-opioid therapeutics to treat peripheral neuopathic pain. Inspired by the fish-hunting marine cone snails, we have developed the most potent and selective activators of the new, recently clinicallly validated pain target, the somatostatin receptor 4.

Our inital target indication is diabetic peripheral neuropathy, a detrimental persitent pain that is currently extremely difficult to treat. The dedicated team at Akasi Pharma is working to provide the best-in-class solutions for these patients.

Team

Walden Bjørn-Yoshimoto

Founder, CEO

Expert in pharmaceutical sciences with a background in both academia and biotech startup.

Helena Safavi

Founder, CSO

Peptide biological mimicry expert with an extensive academic track record.

Sophie Heiden Laugesen

COO

Expert project manager with a background in insulin drug biology

Pipeline

Our novel pain asset, AP-1001, is currently undergoing lead optimization. Our initial focus indication is diabetic peripeheral neuropathy (DPN). We expect to dose the first human in Q1 of 2028, and finish our phase 2a trial by the end-of-year 2030.

Pipeline

Our novel pain asset, AP-1001, is currently undergoing lead optimization. We expect to dose the first human in Q1 of 2028, and finish our phase 2 trial by the end-of-year 2030.

Contact Us

If you’d like to get in touch, feel free to reach out via email or visit us at our office.

Follow us!